Recent Updates
Recently added Catalysts
INDV Positive Sentiment Score: 65/100

Indivior Announces Q3 2024 Financial Results Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024. The earnings release, investor...

Key Takeaway: Indivior PLC announced its financial results for the third quarter of 2024, highlighting its ongoing efforts to tackle substance use disorders and related mental health conditions. The company's CEO, Mark Crossley, will host a live webcast to discuss the earnings in detail. Indivior aims to expand its portfolio of treatments for opioid use disorders and provide access to care on a global scale. The company operates from Richmond, VA and serves markets in over 30 countries.

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior reported its financial results for Q3 2024, indicating continued business activity.
  • The company emphasizes its commitment to addressing substance use disorders and mental health.
  • Indivior plans to host a live webcast to discuss earnings, showcasing transparency.

Full Press Release Details

SLOUGH, United Kingdom and RICHMOND, Va. , Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024 . The earnings release, investor presentation and webcast are available at www.indivior.com .
There will be a live webcast presentation at 13:00 BST ( 8:00 am ET ) hosted by Mark Crossley , CEO. The details are below.
Webcast link: https://edge.media-server.com/mmc/p/ppm4ske8 Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BId4d5b45a6f3e4291ba42150c1620fc64 (Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA , Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .
SOURCE Indivior PLC

21 %

Frequently Asked Questions

What did Indivior announce on October 24, 2024?

Indivior PLC announced its financial results for the period ending September 30, 2024.

Who will host the live webcast presentation?

The live webcast presentation will be hosted by Mark Crossley, the CEO.

What is Indivior's mission?

Indivior aims to develop medicines to treat substance use disorders and mental illnesses.

Where is Indivior headquartered?

Indivior is headquartered in Richmond, Virginia, USA.

In how many countries is Indivior's product portfolio available?

Indivior's product portfolio is available in over 30 countries worldwide.

Last updated: Oct 24, 2024